Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs Iambic Therapeutics, Inc. (IAM)

Aclaris Therapeutics, Inc. and Iambic Therapeutics, Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Iambic Therapeutics, Inc. are of similar size ($559.5M and $551.7M).

Valuation

Metric ACRS IAM Biotechnology median
P/E n/m — 10.60
P/S 90.59 — 9.40
P/B 3.48 — 2.13
Price to free cash flow n/m — 25.18
EV/EBITDA n/m — 0.66
EV/Sales 74.41 — 9.02
Earnings yield (14.95%) — (32.88%)
Free cash flow yield (12.99%) — (23.13%)

Profitability

Metric ACRS IAM Biotechnology median
Gross margin 0.00% — 68.51%
Operating margin (1,413.97%) — 0.00%
Net margin (1,244.09%) — 0.00%
Free cash flow margin (1,176.61%) — 0.00%
Return on equity (55.51%) — (51.96%)
Return on assets (40.66%) — (46.06%)
Return on invested capital (107.72%) — 0.00%

Growth

Metric ACRS IAM Biotechnology median
Revenue growth (TTM) (59.34%) — 6.76%
EPS growth (last fiscal year) 69.01% — 29.88%
Revenue growth, 5-year CAGR 3.84% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ACRS IAM Biotechnology median
Debt to equity 0.00 — 0.00
Current ratio 5.09 — 4.97
Net debt to EBITDA 1.20 — 1.01

Dividend

Metric ACRS IAM Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACRS IAM Biotechnology median
Market cap 559.49m 551.74m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack